Cyclooxygenase-2 (COX-2) negatively regulates expression of epidermal growth factor receptor and causes resistance to gefitinib in COX-2-overexpressing cancer cells

Molecular Cancer Research

Volumn 7, Issue 8, 2009, Pages 1367-1377

  Young, Mee Kim ^a   Park, Soo Yeon ^a   Pyo, Hongryull ^a  

^a National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 (8 AMINOMETHYL 6,7,8,9 TETRAHYDROPYRIDO[1,2 A]INDOL 10 YL) 4 (1 METHYL 3 INDOLYL) 1H PYRROLE 2,5 DIONE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; CELECOXIB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROSTAGLANDIN E2; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL LINE; CELL STRAIN HCT116; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY;

CYCLOOXYGENASE 2; DINOPROSTONE; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 69449097219     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0004     Document Type: Article

References (34)

1. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention.J Clin Oncol 2005;23:254-266
2. Half E, Sun Y, Sinicrope FA. Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells.Cancer Lett 2007;251:237-246
3. Yang L, Amann JM, Kikuchi T, et al. Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small- cell lung cancer.Cancer Res 2007;67:5587-5593
4. Singh B, Berry JA, Shoher A, Ayers GD, Wei C, Lucci A. COX-2 involvement in breast cancer metastasis to bone.Oncogene 2007;26:3789-3796
5. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange.Cancer Res 2007;67:3976-3985
6. Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.J Natl Cancer Inst 2006;98:736-747
7. Chang YW, Marlin JW, Chance TW, Jakobi R. RhoA mediates cyclooxygenase-2 signaling to disrupt the formation of adherens junctions and increase cell motility.Cancer Res 2006;66:11700-11708
8. Tsai WC, Tsai ST, Jin YT, Wu LW. Cyclooxygenase-2 is involved in S100A2-mediated tumor suppression in squamous cell carcinoma.Mol Cancer Res 2006;4:539-547
9. Watwe V, Javle M, Lawrence D, et al. Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer.Am J Clin Oncol 2005;28:560-564
10. Kiefer JR, Pawlitz JL, Moreland KT, et al. Structural insights into the stereochemistry of the cyclooxygenase reaction.Nature 2000;405:97-101.
11. Im JY, Kim D, Paik SG, Han PL. Cyclooxygenase-2-dependent neuronal death proceeds via superoxide anion generation.Fre e Rad Biol Med 2006;41:960-972
12. Cipollone F. COX-2 and prostaglandins in atherosclerosis. Lupus 2005;14:756-759
13. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.S cience 2004;305:1163-1167
14. Xu H, Yu Y, Marciniak D, et al. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.Mol Cancer Ther 2005;4:435-442
15. Chen Z, Zhang X, Li M, et al. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.Cl in Cancer Res 2004;10:5930-5939
16. Park JS, Jun HJ, Cho MJ, et al. Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells.Clin Cancer Res 2006;12:4989-4999
17. Zhang X, Chen ZG, Choe MS, et al. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.Clin Cancer Res 2005;11:6261-6269
18. Sminia P, Stoter TR, van der Valk P, et al. Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent glioblastoma multiforme. J Cancer Res Clin Oncol 2005;131:653-661 (Pubitemid 41502208)
19. Lanza-Jacoby S, Burd R, Rosato FE, Jr., et al. Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/ neu-positive breast cancer.Clin Cancer Res 2006;12:6161-6169
20. Choe MS, Zhang X, Shin HJ, Shin DM, Chen ZG. Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 2005;4:1448-1455
21. Shin YK, Park JS, Kim HS, et al. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res 2005;65:9501-9509
22. Kang HK, Lee E, Pyo H, Lim SJ. Cyclooxygenase-independent downregulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells.Mo l Cancer Ther 2005;4:1358-1363
23. Krysan K, Reckamp KL, Dalwadi H, et al. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner.Ca ncer Res 2005;65:6275-6281
24. Wang XQ, Yan Q, Sun P, et al. Suppression of epidermal growth factor receptor signaling by protein kinase C-α activation requires CD82, caveolin-1, and ganglioside.Cancer Res 2007;67:9986-9995
25. Zhang L, Jiang L, Sun Q, et al. Prostaglandin E(2) enhances mitogen-activated protein kinase/Erk pathway in human cholangiocarcinoma cells: involvement of EP1 receptor, calcium and EGF receptors signaling.Mol Cell Biochem 2007.
26. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.Oncogene 2007;26:3291-3310
27. Mialon A, Sankinen M, Soderstrom H, et al. DNA topoisomerase I is a co-factor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation.Mol Cell Biol 2005;25:5040-5051
28. Crotty T, Cai J, Sakane F, Taketomi A, Prescott SM, Topham MK. Diacylglycerol kinase δ regulates protein kinase C and epidermal growth factor receptor signaling.Proc Natl Acad Sci U S A 2006;103:15485-15490
29. 2-terminal kinase regulation but does not cause a measurable defect in NF-κB activation. Proc Natl Acad Sci U S A 2000;97:7272-7277
30. Xu Z, Choudhary S, Voznesensky O, et al. Overexpression of COX-2 in human osteosarcoma cells decreases proliferation and increases apoptosis. Cancer Res 2006;66:6657-6664 (Pubitemid 44085622)
31. Nishimura Y, Yoshioka K, Bereczky B, Itoh K. Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line. Mol Cancer 2008;7:42. (Pubitemid 351803809)
32. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-655 (Pubitemid 40812628)
33. Vokes EE, Choy H. Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting.Lung Cancer 2003;41 Suppl 1:S115-21.
34. Javle MM, Yu J, Khoury T, et al. Akt expression may predict favorable prognosis in cholangiocarcinoma.J Gastroenterol Hepatol 2006;21:1744-1751